Welcome to our dedicated page for Draegerwerk news (Ticker: DGWPF), a resource for investors and traders seeking the latest updates and insights on Draegerwerk stock.
Drägerwerk AG & Co. KGaA (DGWPF) drives innovation in life-saving technologies across medical and safety sectors. This news hub provides investors and industry professionals with authoritative updates on the company’s advancements in respiratory systems, emergency response equipment, and critical care solutions.
Access real-time announcements including quarterly earnings reports, product launch details, and strategic partnership updates. Our curated collection ensures transparent access to operational developments impacting both healthcare delivery and industrial safety standards.
Discover updates spanning regulatory milestones, technology patents, and global distribution expansions. Each release is verified for accuracy, providing stakeholders with reliable insights into the company’s market position and engineering breakthroughs.
Bookmark this page for streamlined tracking of DGWPF’s innovations in anesthesia workstations, closed-circuit breathing apparatus, and safety systems designed for extreme environments. Stay informed through systematically organized updates that matter to your financial and operational analysis.
Dräger launches the next-generation Alcotest 7000, an advanced alcohol screening device featuring dual-mode testing capabilities. The device supports law enforcement, DOT compliance, and workplace safety initiatives.
Key innovations include:
- Dual testing modes: funnel-based prescreening and Slide 'n' Click mouthpiece screening
- Bluetooth wireless data transmission
- 2.4" full-color display
- Storage for up to 10,000 test results
- Operating range from -10°F to 131°F
The device offers non-invasive checks for law enforcement operations and meets DOT protocols for workplace testing. Building on 70+ years of alcohol testing expertise, this launch strengthens Dräger's commitment to road safety and impaired driving prevention. The company, which generated revenues of €3 billion in 2023, continues its mission of protecting lives through innovative safety technology.
Dräger (DGWPF) has secured a five-year, single-award Non-Expendable (NX) Equipment Program contract from the Veterans Health Administration (VHA) for surgical lighting systems and equipment booms (Contract # 36C10G24D0105). The agreement enables VA medical facilities to order Dräger's equipment through VHA's National Equipment Catalog (NEC).
The contract features Dräger's Polaris surgical lighting systems, designed to enhance surgical precision and workflow efficiency while managing operational costs. The NX Equipment Program aims to simplify procurement and improve purchasing efficiency for VA facilities through a pre-competed acquisition option.
Dräger, with revenues of €3.4 billion in 2024 and operations in over 190 countries, specializes in medical and safety technology with a global workforce exceeding 16,000 employees.
Dräger (DGWPF) and VirtualiSurg have been awarded the inaugural Obsidian Award for their Babyleo XR extended reality simulator, designed for NICU medical team training. The project, developed through a collaboration that began in 2021, combines clinical training with communication and compassion skills for healthcare professionals.
The simulator features multi-user functionality, parent-focused content, and dialogue training for sensitive topics. The training content was developed based on expert interviews, scientific literature, and hundreds of parental stories. The award ceremony took place on December 5, 2024, in Rotterdam during Immersive Tech Week Congress, where the project competed alongside tech giants Meta and HTC.
Dräger, an international medical and safety technology company founded in 1889, generated global sales of approximately EUR 3 billion in 2022 and operates in over 190 countries with more than 14,000 employees.
Dräger has expanded its neonatal care portfolio by introducing BiliPredics, a predictive software solution developed by NeoPredics for forecasting bilirubin progression in newborns. The innovative digital application can predict bilirubin levels up to 60 hours in advance, utilizing a database of over 50,000 bilirubin measurements from nearly 10,000 newborns.
The software aims to enhance jaundice management, which affects approximately 50% of all newborns and up to 80% of premature babies. BiliPredics integrates with electronic medical records and aligns with the 2022 AAP Hyperbilirubinemia Guideline, requiring minimal clinical parameters to generate insights.
The solution complements Dräger's existing jaundice management products, including the Jaundice Meter JM-105 for non-invasive measurements and the BiliLux Phototherapy Light for treatment. This comprehensive approach supports enhanced discharge planning and data-driven decision-making in neonatal care.
Dräger (DGWPF) has unveiled the ProAir, a NIOSH-approved closed-circuit breathing apparatus (CCBA) designed for first responders. The innovative device provides up to four hours of continuous oxygen supply, specifically targeting rescue operations in high-rise buildings, tunnels, and subways.
The ProAir features proprietary CO2 scrubbing technology and introduces two cooling options: the Ice Cooler and the Phase Change Material (PCM) system. Key features include flame resistance up to 1,742°F, Buddy Lights for team awareness, and an Electronic Control Unit for monitoring critical supplies.
The device addresses growing urban challenges, with over 1,110 U.S. skyscrapers exceeding 490 feet and 1.4 million multi-unit housing completions in 2024. U.S. fire departments can acquire the ProAir through the Assistance to Firefighters Grant Program.
Dräger (DGWPF) has unveiled the NIOSH-certified ProAir, an advanced closed-circuit breathing apparatus (CCBA) designed for Federal Government operations. The device provides up to four hours of continuous oxygen supply, significantly surpassing traditional SCBAs' 45-60 minute capacity.
The ProAir features innovative technology including:
- Proprietary CO2 scrubber with RFID tracking
- Two cooling options: Ice Cooler and Phase Change Material system
- Flame resistance up to 1,742°F
- Electronic Control Unit for real-time status monitoring
- Integrated radio and voice amplification features
The device is specifically designed for hazardous environments including below-deck ship incidents, confined spaces, subterranean operations, and HAZMAT operations. It aims to enhance operational capabilities for federal agencies, armed forces, law enforcement, and emergency responders by eliminating frequent cylinder changes during prolonged engagements.
Dräger announced that its Evita V800/V600 and Babylog VN800 family of mechanical ventilators received Authority to Operate (ATO) certification under the Department of Defense's Risk Management Framework (RMF) eMASS #3984. Additionally, the Savina 300 series received ATO certification under eMASS #3957. Both certifications are effective from January 23, 2025, and expire on January 21, 2028.
This certification follows Dräger's previous achievement with the V500 series ventilators in 2020. The ATO certification represents the highest level of security for medical devices, offering benefits such as enhanced data protection, compliance assurance, and faster integration with hospital systems. These certifications demonstrate Dräger's commitment to cybersecurity and patient data protection.
Dräger has received an Innovative Technology Product designation from Vizient for its Atlan® A350/A350XL Anesthesia Machines. The designation, awarded by Vizient (the largest healthcare performance improvement company in the US), recognizes products that enhance clinical care, patient safety, and healthcare operations.
The Atlan family of anesthesia workstations features an electronic piston ventilator for precise ventilation across all patient ages, extensive safety features, and optimization for low-flow anesthesia. The system includes a Low Flow Wizard tool and recycling of sampled breathing gas, reducing anesthetic agent consumption and environmental impact.
Dräger, which generated revenues of €3.4 billion in 2023 and operates in over 190 countries, is a Vizient Pediatric Program supplier in four categories: Anesthesia Machines, Infant Care and Phototherapy, Ventilators, and OR Lights, Columns, and Booms.
Dräger, a global safety technology leader, has introduced the OXY SR Cap III, an innovative respiratory protective device for emergency escape in extreme underground and confined space environments. This NIOSH-certified device provides 90 liters of oxygen for safe evacuation from life-threatening situations.
Key features include:
- Fast activation and oxygen delivery
- Up to 10 years of maintenance-free service life
- Designed for universal usability with a simple 5-step deployment process
- Automatic activation when the mouthpiece is pulled
- Safety Eye indicator for quick damage assessment
- Cost-effective solution with reduced lifetime costs
The OXY SR Cap III is suitable for mining, tunneling, industrial facilities, railways, and subways, offering critical protection against fire, toxic chemical exposure, and oxygen deficiency.
Dräger has been awarded the 2024 Zenith Award by the American Association for Respiratory Care (AARC), marking the 13th time the company has received this recognition. The award, given to only eight out of over 300 companies, is based on criteria including equipment quality, service, and customer support. Dräger's commitment to the respiratory care profession is highlighted by its continuous investment in new technologies, such as the Evita V600, V800, and Babylog VN800 ventilators.
The company's services include a network of over 3000 technicians, remote service, and 24/7 hotline support. Dräger has also donated more than 320 ventilators to respiratory schools in the United States for training purposes. With revenues of around €3.4 billion in 2023, Dräger operates in over 190 countries with more than 16,000 employees worldwide.